20 Jul Satellite Bio
Tom Lowery, Ph.D., President and Chief Technology Officer
Oct. 7 | 1:30pm | FLW Ballroom G
Watertown, MA
(Private)
Satellite is harnessing the therapeutic potential of hepatocytes to tackle advanced liver disease.
A shortage of organs coupled with high complexity of surgery makes transplantation unrealistic for >85% of those in need. Cell therapies have promise, but widespread use of primary hepatocytes is severely limited by availability, and stem cell-derived hepatocytes do not have the appropriate level of functionality. As pioneers of regenerative medicine, we are the first company to develop protocols to effectively isolate, expand and mature hepatocytes, generating fully functional cells. Akin to a liver transplant via infusion, our powerful and precisely organized cells are delivered into the body where they engraft and vascularize, acting like a mini “satellite” organ that boosts or restores liver functions. By creating a sustainable cell source, we can shatter the 1:1 paradigm of liver transplants. With Tissue Therapeutics, we could benefit a thousand patients from a single organ – an enormous opportunity for the hundreds of thousands of patients in need.
